Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Listen to our conference call with Outlook Therapeutics management to learn more about the pivotal data.



October 12, 2021
Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab
October 7, 2021 Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).


ONS-5010/ LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity.

ONS-5010 has completed the pivotal clinical trial in our Phase 3 program for wet AMD and is expected to be submitted with the FDA as a new BLA for this ophthalmic indication in the first calendar quarter of 2022. Outlook Therapeutics also intends to commence additional clinical trials for ONS-5010 in DME and BRVO.

If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab to treat retinal diseases.